Document_and_Entity_Informatio
Document and Entity Information | 3 Months Ended | |
Mar. 31, 2015 | Apr. 24, 2015 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | FALSE | |
Document Period End Date | 31-Mar-15 | |
Document Fiscal Year Focus | 2015 | |
Document Fiscal Period Focus | Q1 | |
Trading Symbol | ATRC | |
Entity Registrant Name | AtriCure, Inc. | |
Entity Central Index Key | 1323885 | |
Current Fiscal Year End Date | -19 | |
Entity Filer Category | Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 28,370,298 |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (Unaudited) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Thousands, unless otherwise specified | ||
Current assets: | ||
Cash and cash equivalents | $23,559 | $28,384 |
Short-term investments | 32,174 | 31,265 |
Accounts receivable, less allowance for doubtful accounts of $162 and $68, respectively | 19,786 | 17,558 |
Inventories | 15,106 | 14,257 |
Other current assets | 2,790 | 2,044 |
Total current assets | 93,415 | 93,508 |
Property and equipment, net | 13,874 | 11,552 |
Long-term investments | 2,025 | 8,894 |
Intangible assets, net | 8,575 | 8,878 |
Goodwill | 35,386 | 35,386 |
Other noncurrent assets | 131 | 186 |
Total Assets | 153,406 | 158,404 |
Current liabilities: | ||
Accounts payable | 9,659 | 7,621 |
Accrued liabilities | 8,974 | 14,041 |
Other current liabilities and current maturities of capital leases | 5,996 | 3,981 |
Total current liabilities | 24,629 | 25,643 |
Capital leases | 79 | 74 |
Other noncurrent liabilities | 139 | 149 |
Total Liabilities | 24,847 | 25,866 |
Commitments and contingencies (Note 7) | ||
Stockholders' Equity: | ||
Common stock, $0.001 par value, 90,000 shares authorized and 28,363 and 27,580 issued and outstanding, respectively | 28 | 28 |
Additional paid-in capital | 273,019 | 271,282 |
Accumulated other comprehensive loss | -798 | -348 |
Accumulated deficit | -143,690 | -138,424 |
Total Stockholders' Equity | 128,559 | 132,538 |
Total Liabilities and Stockholders' Equity | $153,406 | $158,404 |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Thousands, except Share data, unless otherwise specified | ||
Statement of Financial Position [Abstract] | ||
Accounts receivable, allowance for doubtful accounts | $162 | $68 |
Common stock, par value | $0.00 | $0.00 |
Common stock, shares authorized | 90,000,000 | 90,000,000 |
Common stock, shares issued | 28,363,000 | 27,580,000 |
Common stock, shares outstanding | 28,363,000 | 27,580,000 |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $) | 3 Months Ended | |
In Thousands, except Per Share data, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Income Statement [Abstract] | ||
Revenue | $29,886 | $24,847 |
Cost of revenue | 8,151 | 7,190 |
Gross profit | 21,735 | 17,657 |
Operating expenses: | ||
Research and development expenses | 5,609 | 4,001 |
Selling, general and administrative expenses | 21,270 | 21,581 |
Total operating expenses | 26,879 | 25,582 |
Loss from operations | -5,144 | -7,925 |
Other income (expense): | ||
Interest expense | -18 | -237 |
Interest income | 43 | 14 |
Other | -141 | 466 |
Loss before income tax expense | -5,260 | -7,682 |
Income tax expense | 6 | 27 |
Net loss | -5,266 | -7,709 |
Basic and diluted net loss per share | ($0.19) | ($0.31) |
Weighted average shares outstanding-basic and diluted | 27,069 | 24,766 |
Comprehensive loss: | ||
Unrealized gains (losses) on investments | 37 | -2 |
Foreign currency translation adjustment | -487 | 2 |
Other comprehensive loss | -450 | |
Net loss | -5,266 | -7,709 |
Comprehensive loss | ($5,716) | ($7,709) |
Condensed_Consolidated_Stateme1
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Cash flows from operating activities: | ||
Net loss | ($5,266) | ($7,709) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Share-based compensation expense | 1,724 | 2,142 |
Depreciation | 1,008 | 730 |
Amortization of intangible assets | 303 | 355 |
Amortization of deferred financing costs | 16 | 59 |
Loss on disposal of property and equipment | 57 | 14 |
Realized loss from foreign exchange on intercompany transactions | 251 | |
Amortization/accretion on investments | 184 | 83 |
Change in allowance for doubtful accounts | 100 | -17 |
Other | 95 | |
Changes in operating assets and liabilities: | ||
Accounts receivable | -2,685 | -1,045 |
Inventories | -1,104 | -862 |
Other current assets | -779 | 312 |
Accounts payable | 2,124 | -531 |
Accrued liabilities | -4,931 | -7,969 |
Other noncurrent assets and liabilities | 28 | -55 |
Net cash used in operating activities | -8,970 | -14,398 |
Cash flows from investing activities: | ||
Purchases of available-for-sale securities | -6,086 | |
Sales and maturities of available-for-sale securities | 11,899 | 8,434 |
Purchases of property and equipment | -1,434 | -1,020 |
Increases in property under build-to-suit obligation | -1,822 | |
Net cash provided by investing activities | 2,557 | 7,414 |
Cash flows from financing activities: | ||
Proceeds from sale of stock, net of offering costs of $0 and $215, respectively | 65,872 | |
Payments on debt and capital leases | -14 | -6,343 |
Increases in build-to-suit obligation | 1,822 | |
Payment of debt fees and premium on retirement of debt | -100 | |
Proceeds from stock option exercises | 516 | 1,395 |
Shares repurchased for payment of taxes on stock awards | -503 | -88 |
Net cash provided by financing activities | 1,821 | 60,736 |
Effect of exchange rate changes on cash and cash equivalents | -233 | -5 |
Net (decrease) increase in cash and cash equivalents | -4,825 | 53,747 |
Cash and cash equivalents-beginning of period | 28,384 | 14,892 |
Cash and cash equivalents-end of period | 23,559 | 68,639 |
Supplemental cash flow information: | ||
Cash paid for interest | 2 | 102 |
Cash paid for taxes | 146 | |
Non-cash investing and financing activities: | ||
Accrued purchases of property and equipment | 751 | 124 |
Assets acquired through capital lease | $36 |
Condensed_Consolidated_Stateme2
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Statement of Cash Flows [Abstract] | ||
Offering cost for sale of stock | $0 | $215 |
Description_of_Business_and_Su
Description of Business and Summary of Significant Accounting Policies | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Accounting Policies [Abstract] | |||||||||
Description of Business and Summary of Significant Accounting Policies | 1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||||||||
Nature of the Business—AtriCure, Inc. was incorporated in the State of Delaware on October 31, 2000. The “Company” or “AtriCure” consists of AtriCure, Inc. and its wholly-owned subsidiaries. The Company is an innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM). The Company sells its products to medical centers globally through a direct sales force and distributors. | |||||||||
Basis of Presentation—The accompanying interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC). The accompanying interim financial statements are unaudited, but in the opinion of the Company’s management, contain all of the normal, recurring adjustments considered necessary to present fairly the financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America (GAAP) applicable to interim periods. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been omitted or condensed. The Company believes the disclosures herein are adequate to make the information presented not misleading. Results of operations are not necessarily indicative of the results expected for the full fiscal year or for any future period. | |||||||||
The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the audited financial statements of the Company included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC. | |||||||||
Principles of Consolidation—The Condensed Consolidated Financial Statements include the accounts of the Company, AtriCure, LLC, the Company’s wholly-owned subsidiary organized in the State of Delaware, Endoscopic Technologies, LLC, the Company’s wholly-owned subsidiary organized in the State of Delaware, and AtriCure Europe B.V. (AtriCure Europe), the Company’s wholly-owned subsidiary incorporated in the Netherlands. All intercompany accounts and transactions have been eliminated in consolidation. | |||||||||
Cash and Cash Equivalents—The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents. | |||||||||
Investments—The Company places its investments primarily in U.S. Government agencies and securities, corporate bonds and commercial paper. The Company classifies all investments as available-for-sale. Investments with maturities of less than one year are classified as short-term investments. Investments are recorded at fair value, with unrealized gains and losses recorded as accumulated other comprehensive income (loss). The Company recognizes gains and losses when these securities are sold using the specific identification method and includes them in interest income or expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss. | |||||||||
Revenue Recognition—The Company accounts for revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 605, “Revenue Recognition” (ASC 605). The Company recognizes revenue when all of the following criteria are met: (i) there is persuasive evidence that an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectability is reasonably assured. | |||||||||
Pursuant to the Company’s standard terms of sale, revenue is recognized when title to the goods and risk of loss transfers to customers and there are no remaining obligations that will affect the customers’ final acceptance of the sale. Generally, the Company’s standard terms of sale define the transfer of title and risk of loss to occur upon shipment to the respective customer. The Company generally does not maintain any post-shipping obligations to the recipients of the products. No installation, calibration or testing of this equipment is performed by the Company subsequent to shipment to the customer in order to render it operational. | |||||||||
Revenue includes shipping and handling revenue of $247 and $227 for the three months ended March 31, 2015 and 2014, respectively. Cost of freight for shipments made to customers is included in cost of revenue. Sales and other value-added taxes collected from customers and remitted to governmental authorities are excluded from revenue. The Company sells its products primarily through a direct sales force, with certain international markets sold through distributors. Terms of sale are generally consistent for both end-users and distributors except that payment terms are generally net 30 days for end-users and net 60 days for distributors. | |||||||||
Sales Returns and Allowances—The Company maintains a provision for sales returns and allowances to account for potential returns of defective or damaged products, products shipped in error and invoice adjustments. The Company estimates such provision quarterly based primarily on a specific identification basis, in addition to estimating a general reserve. Increases to the provision result in a reduction of revenue. The provision is included in accrued liabilities in the Condensed Consolidated Balance Sheets. | |||||||||
Allowance for Doubtful Accounts Receivable—The Company evaluates the collectability of accounts receivable in order to determine the appropriate reserve for doubtful accounts. In determining the amount of the reserve, the Company considers aging of account balances, historical credit losses, customer-specific information and other relevant factors. An increase to the allowance for doubtful accounts results in a corresponding increase in expense. The Company reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables against the allowance when all attempts to collect the receivable have failed. The Company’s history of write-offs against the allowance has not been significant. | |||||||||
Inventories—Inventories are stated at the lower of cost or market using approximate costs based on the first-in, first-out cost method (FIFO) and consist of raw materials, work in process and finished goods. The Company’s industry is characterized by rapid product development and frequent new product introductions. Uncertain timing of product approvals, variability in product launch strategies and variation in product utilization all impact excess and obsolete inventory. An inventory reserve based on product usage is estimated and recorded quarterly for excess, slow moving and obsolete inventory, as well as inventory with a carrying value in excess of its net realizable value. Write-offs are recorded when a product is destroyed. The Company’s history of write-offs against the reserve has not been significant. | |||||||||
Inventories consist of the following: | |||||||||
March 31, | December 31, | ||||||||
2015 | 2014 | ||||||||
Raw materials | $ | 4,484 | $ | 4,429 | |||||
Work in process | 1,169 | 1,397 | |||||||
Finished goods | 9,453 | 8,431 | |||||||
Inventories | $ | 15,106 | $ | 14,257 | |||||
Property and Equipment—Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method of depreciation for financial reporting purposes and applied over the estimated useful lives of the assets. The estimated useful life by major asset category is the following: generators and other capital equipment, machinery, equipment and vehicles is three to seven years, computer and other office equipment is three years, furniture and fixtures is three to seven years and leasehold improvements and equipment leased under a capital lease are the shorter of their useful life or remaining lease term. The Company reassesses the useful lives of property and equipment annually, and assets are retired if they are no longer being used. Maintenance and repair costs are expensed as incurred. | |||||||||
Generators and other capital equipment (such as the Company’s switchbox units and cryosurgical consoles) are loaned at no cost to direct customers that use the Company’s disposable products. Depreciation of such assets is included in cost of revenue. The estimated useful lives of this equipment are based on anticipated usage by customers and the timing and impact of expected new technology rollouts by the Company. To the extent the Company experiences changes in the usage of this equipment or introduces new technologies, the estimated useful lives of this equipment may change in a future period. Depreciation related to these generators was $620 and $461 for the three months ended March 31, 2015 and 2014, respectively. As of March 31, 2015 and December 31, 2014, the net carrying amount of loaned equipment included in net property and equipment in the Condensed Consolidated Balance Sheets was $4,123 and $4,141, respectively. | |||||||||
The Company reviews property and equipment for impairment using its best estimates based on reasonable and supportable assumptions and projections. | |||||||||
Intangible Assets—Intangible assets with determinable useful lives are amortized on a straight-line basis over the estimated periods benefited. The Company reviews intangible assets for impairment using its best estimates based on reasonable and supportable assumptions and projections. | |||||||||
Goodwill—Goodwill represents the excess of purchase price over the fair value of the net assets acquired in business combinations. The Company tests goodwill for impairment annually on November 30, or more often if impairment indicators are present. The Company’s goodwill is accounted for in a single reporting unit representing the Company as a whole. | |||||||||
Other Current Liabilities and Current Maturities of Capital Leases—Other current liabilities consist of a financing obligation related to the construction of the Company’s new headquarters (see Note 7—Commitments and Contingencies). Current maturities of capital leases consist of capital lease obligations with maturities of less than one year (see Note 6—Indebtedness). | |||||||||
Other Income—Other income consists primarily of foreign currency transaction gains and losses, grant income and non-employee option gains and losses related to the fair market value change for fully vested options outstanding for consultants which are accounted for as free-standing derivatives. | |||||||||
The Company recorded net foreign currency transaction (losses) gains of ($163) and $5 for the three months ended March 31, 2015 and 2014, respectively, primarily in connection with settlements of its intercompany balance with AtriCure Europe. | |||||||||
The Company periodically is awarded grants to support research and development activities or education activities. The Company recognizes grant income when the funds are earned. The Company recorded grant income of $35 and $363 during the three months ended March 31, 2015 and 2014, respectively. | |||||||||
The Company historically issued stock options to non-employee consultants as a form of compensation for services provided to the Company. Because the non-employee options require settlement by the Company’s delivery of registered shares and because the tax withholding provisions in the awards allow the options to be partially net-cash settled, these options, when vested, are no longer eligible for equity classification and are, thus, subsequently accounted for as derivative liabilities under FASB ASC 815, “Derivatives and Hedging” (ASC 815) until the awards are ultimately either exercised or forfeited. Accordingly, the vested non-employee options are classified as liabilities and remeasured at fair value through earnings at each reporting period. During the three months ended March 31, 2015 and 2014, $13 and ($98), respectively, of expense (income) was recorded as a result of the remeasurement of the fair value of these fully vested stock options. | |||||||||
Taxes—Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in the period that includes the enactment date. | |||||||||
The Company’s estimate of the valuation allowance for deferred tax assets requires it to make significant estimates and judgments about its future operating results. Deferred tax assets are reduced by valuation allowances if, based on the consideration of all available evidence, it is more-likely-than-not that some portion of the deferred tax asset will not be realized. Significant weight is given to evidence that can be objectively verified. The Company evaluates deferred tax assets on a quarterly basis to determine if valuation allowances are required by considering all available evidence. Deferred tax assets are realized by having sufficient future taxable income to allow the related tax benefits to reduce taxes otherwise payable. The sources of taxable income that may be available to realize the benefit of deferred tax assets are future reversals of existing taxable temporary differences, future taxable income, exclusive of reversing temporary differences and carryforwards, taxable income in carry-back years and tax planning strategies that are both prudent and feasible. In evaluating whether to record a valuation allowance, the applicable accounting standards deem that the existence of cumulative losses in recent years is a significant piece of objectively verifiable negative evidence that must be overcome by objectively verifiable positive evidence to avoid the need to record a valuation allowance. The Company has recorded a full valuation allowance against its net deferred tax assets as it is more-likely-than-not that the benefit of the deferred tax assets will not be recognized in future periods. | |||||||||
A provision of The Patient Protection and Affordable Care Act enacted in 2010, as amended (Affordable Care Act), requires manufacturers of medical devices to pay an excise tax on all U.S. medical device sales. The Company’s expense related to the medical device excise tax, which was recorded in cost of revenue, was $155 and $114 for the three months ended March 31, 2015 and 2014, respectively. | |||||||||
Net Loss Per Share—Basic and diluted net loss per share is computed in accordance with FASB ASC 260, “Earnings Per Share” (ASC 260) by dividing the net loss by the weighted average number of common shares outstanding during the period. Since the Company has experienced net losses for all periods presented, net loss per share excludes the effect of 4,320 and 3,762 options and restricted stock shares as of March 31, 2015 and 2014, respectively, because they are anti-dilutive. Therefore the number of shares calculated for basic net loss per share is also used for the diluted net loss per share calculation. | |||||||||
Comprehensive Loss and Accumulated Other Comprehensive Loss—In addition to net losses, the comprehensive loss includes foreign currency translation adjustments and unrealized gains and losses on investments. | |||||||||
Accumulated other comprehensive income (loss) consisted of the following: | |||||||||
Three Months Ended March 31, | |||||||||
2015 | 2014 | ||||||||
Total accumulated other comprehensive loss at beginning of period | $ | (348 | ) | $ | (139 | ) | |||
Unrealized Loss on Investments | |||||||||
Balance at beginning of period | $ | (54 | ) | $ | (6 | ) | |||
Other comprehensive income (loss) before reclassifications | 37 | (2 | ) | ||||||
Amounts reclassified from accumulated other comprehensive income (loss) to other income | — | — | |||||||
Balance at end of period | $ | (17 | ) | $ | (8 | ) | |||
Foreign Currency Translation Adjustment | |||||||||
Balance at beginning of period | $ | (294 | ) | $ | (133 | ) | |||
Other comprehensive loss before reclassifications | (324 | ) | (3 | ) | |||||
Amounts reclassified from accumulated other comprehensive loss to other income (expense) | (163 | ) | 5 | ||||||
Balance at end of period | $ | (781 | ) | $ | (131 | ) | |||
Total accumulated other comprehensive loss at end of period | $ | (798 | ) | $ | (139 | ) | |||
Research and Development—Research and development costs are expensed as incurred. These costs include compensation and other internal and external costs associated with the development and research related to new and existing products or concepts, preclinical studies, clinical trials, healthcare compliance and regulatory affairs. | |||||||||
Advertising Costs—The Company expenses advertising costs as incurred. Advertising costs were not significant during the three months ended March 31, 2015 and 2014. | |||||||||
Share-Based Compensation—The Company follows FASB ASC 718, “Compensation-Stock Compensation” (ASC 718) to record share-based compensation for all employee share-based payment awards, including stock options, restricted stock, performance shares and stock purchases related to an employee stock purchase plan, based on estimated fair values. The Company’s share-based compensation expense recognized under ASC 718 for the three months ended March 31, 2015 and 2014 was $1,724 and $2,142, respectively, on a before and after tax basis. | |||||||||
FASB ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s Condensed Consolidated Statement of Operations and Comprehensive Loss. The expense has been reduced for estimated forfeitures. FASB ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. | |||||||||
The Company estimates the fair value of time-based options on the date of grant using the Black-Scholes option-pricing model (Black-Scholes model). The Company’s determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price, as well as assumptions regarding a number of subjective variables. These variables include, but are not limited to, the Company’s expected stock price volatility over the term of the awards and actual and projected employee stock option exercise behaviors. The fair value of market-based performance option grants is estimated at the date of grant using a Monte-Carlo simulation. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Condensed Consolidated Statements of Operations and Comprehensive Loss. | |||||||||
The Company estimates the fair value of restricted stock based upon the grant date closing market price of the Company’s common stock. The Company’s determination of fair value is affected by the Company’s stock price as well as assumptions regarding the number of shares expected to be granted. | |||||||||
The Company also has an employee stock purchase plan (ESPP or the Plan) which is available to all eligible employees as defined by the Plan. Under the ESPP, shares of the Company’s common stock may be purchased at a discount. The Company estimates the number of shares to be purchased under the Plan and records compensation expense based upon the fair value of the stock at the beginning of the purchase period using the Black-Scholes model. | |||||||||
Use of Estimates—The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. | |||||||||
Fair Value Disclosures—The Company classifies and records cash and investments in U.S. government agencies and securities as Level 1 within the fair value hierarchy. Accounts receivable, short-term other assets, accounts payable and accrued liabilities are also classified as Level 1. The carrying amounts of these assets and liabilities approximate their fair value due to their relatively short-term nature. Cash equivalents and investments in commercial paper are classified as Level 2 within the fair value hierarchy (see Note 3—Fair Value for further information). Significant unobservable inputs with respect to the fair value measurement of the Level 3 non-employee stock options are developed using Company data. When an input is changed, the Black-Scholes model is updated and the results are analyzed for reasonableness. |
Recent_Accounting_Pronouncemen
Recent Accounting Pronouncements | 3 Months Ended |
Mar. 31, 2015 | |
Accounting Changes and Error Corrections [Abstract] | |
Recent Accounting Pronouncements | 2. RECENT ACCOUNTING PRONOUNCEMENTS |
In May 2014 the FASB issued a final standard on revenue from contracts with customers. The standard, issued as FASB ASU 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09), outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. In April 2015 the FASB tentatively decided to defer the effective date of ASU 2014-09 for entities reporting under U.S. GAAP from interim and annual reporting periods beginning after December 15, 2016 to interim and annual reporting periods beginning after December 15, 2017. The FASB also tentatively decided to permit entities to early adopt the standard. A full retrospective or modified retrospective approach may be taken to adopt the guidance in the ASU. The Company is evaluating the impact of the provisions of ASU 2014-09 on its consolidated financial position, results of operations and related disclosures. |
Fair_Value
Fair Value | 3 Months Ended | ||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||
Fair Value | 3. FAIR VALUE | ||||||||||||||||
FASB ASC 820, “Fair Value Measurements and Disclosures” (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: | |||||||||||||||||
• | Level 1—Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The valuation under this approach does not entail a significant degree of judgment. | ||||||||||||||||
• | Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The valuation technique for the Company’s Level 2 assets is based on quoted market prices for similar assets from observable pricing sources at the reporting date. | ||||||||||||||||
• | Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. The fair value of the Company’s Level 3 instruments are estimated on the grant date using the Black-Scholes model and they are revalued at the end of each reporting period using the Black-Scholes model. The fair value of the Company’s Level 3 contingent consideration was estimated on the acquisition date of Endoscopic Technologies, Inc. and was revalued at the end of each subsequent reporting period. | ||||||||||||||||
In accordance with ASC 820, the following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2015: | |||||||||||||||||
Quoted Prices in | Significant Other | Significant Other | Total | ||||||||||||||
Active Markets for | Observable Inputs | Unobservable | |||||||||||||||
Identical Assets | (Level 2) | Inputs (Level 3) | |||||||||||||||
(Level 1) | |||||||||||||||||
Assets: | |||||||||||||||||
Money market funds | $ | — | $ | 20,370 | $ | — | $ | 20,370 | |||||||||
U.S. government agencies and securities | 1,021 | — | — | 1,021 | |||||||||||||
Corporate bonds | — | 33,178 | — | 33,178 | |||||||||||||
Total assets | $ | 1,021 | $ | 53,548 | $ | — | $ | 54,569 | |||||||||
Liabilities: | |||||||||||||||||
Derivative instruments | $ | — | $ | — | $ | 134 | $ | 134 | |||||||||
Total liabilities | $ | — | $ | — | $ | 134 | $ | 134 | |||||||||
There were no changes in the levels or methodology of measurement of financial assets and liabilities during the three-month period ended March 31, 2015. | |||||||||||||||||
In accordance with ASC 820, the following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2014: | |||||||||||||||||
Quoted Prices in | Significant Other | Significant Other | Total | ||||||||||||||
Active Markets for | Observable Inputs | Unobservable | |||||||||||||||
Identical Assets | (Level 2) | Inputs (Level 3) | |||||||||||||||
(Level 1) | |||||||||||||||||
Assets: | |||||||||||||||||
Money market funds | $ | — | $ | 23,692 | $ | — | $ | 23,692 | |||||||||
Commercial paper | — | 1,800 | — | 1,800 | |||||||||||||
U.S. government agencies and securities | 3,022 | — | — | 3,022 | |||||||||||||
Corporate bonds | — | 35,337 | — | 35,337 | |||||||||||||
Total assets | $ | 3,022 | $ | 60,829 | $ | — | $ | 63,851 | |||||||||
Liabilities: | |||||||||||||||||
Derivative instruments | $ | — | $ | — | $ | 120 | $ | 120 | |||||||||
Acquisition-related contingent consideration | — | — | — | — | |||||||||||||
Total liabilities | $ | — | $ | — | $ | 120 | $ | 120 | |||||||||
There were no changes in the levels or methodology of measurement of financial assets and liabilities during the twelve months ended December 31, 2014. | |||||||||||||||||
Derivative Instruments. Vested non-employee options historically issued by the Company are accounted for as derivative liabilities and remeasured at fair value through earnings at each reporting period until exercised or forfeited. The Black-Scholes model is used to estimate the fair value of these options at each reporting date using the Company’s stock price and an assumed risk-free interest rate, contractual life, expected volatility and dividend yield. Due to the lack of certain observable market quotes, the Company utilizes valuation models that rely on some Level 3 inputs. The Company’s estimate of volatility is based on the Company’s trading history. | |||||||||||||||||
The fair value of the Level 3 liabilities is estimated using the Black-Scholes model including the following assumptions: | |||||||||||||||||
As of March 31, 2015 | As of December 31, 2014 | ||||||||||||||||
Risk free interest rate | 0.13 | % | 0.07 | % | |||||||||||||
Expected life of option (years) | 0.46 | 0.7 | |||||||||||||||
Expected volatility of stock | 38 | % | 39.91 | % | |||||||||||||
Dividend yield | 0 | % | 0 | % | |||||||||||||
In accordance with ASC 820, the following table represents the Company’s Level 3 fair value measurements using significant other unobservable inputs for derivative instruments as of March 31, 2015: | |||||||||||||||||
Beginning Balance—January 1, 2015 | $ | 120 | |||||||||||||||
Total losses included in earnings | 14 | ||||||||||||||||
Exercises | — | ||||||||||||||||
Reclassification from equity to liability when fully vested | — | ||||||||||||||||
Ending Balance—March 31, 2015 | $ | 134 | |||||||||||||||
In accordance with ASC 820, the following table represents the Company’s Level 3 fair value measurements using significant other unobservable inputs for derivative instruments as of December 31, 2014: | |||||||||||||||||
Beginning Balance—January 1, 2014 | $ | 350 | |||||||||||||||
Total gains included in earnings | (183 | ) | |||||||||||||||
Exercises | (47 | ) | |||||||||||||||
Reclassification from equity to liability when fully vested | — | ||||||||||||||||
Ending Balance—December 31, 2014 | $ | 120 | |||||||||||||||
Acquisition-Related Contingent Consideration. The Company acquired Endoscopic Technologies, Inc. (Estech) on December 31, 2013. The aggregate consideration paid to Estech shareholders includes up to $26,000 of contingent consideration to be paid based on the achievement of certain performance-based milestones in 2014 and 2015. The fair value of the contingent consideration was estimated using an expected present value approach to estimate an expected value, which, in statistical terms, is the weighted average of a discrete random variable’s possible values with the respective probabilities as the weights. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. Using this valuation technique, the fair value of the contingent consideration was determined to be $0 as of both March 31, 2015 and December 31, 2014. | |||||||||||||||||
The following table represents the Company’s Level 3 fair value measurements using significant other unobservable inputs for acquisition-related contingent consideration as of December 31, 2014: | |||||||||||||||||
Beginning Balance—January 1, 2014 | $ | 8,032 | |||||||||||||||
Amounts acquired | — | ||||||||||||||||
Transfers in (out) of Level 3 | — | ||||||||||||||||
Changes in fair value included in earnings | (8,032 | ) | |||||||||||||||
Ending Balance—December 31, 2014 | $ | — | |||||||||||||||
Intangible_Assets
Intangible Assets | 3 Months Ended | ||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||
Intangible Assets | 4. INTANGIBLE ASSETS | ||||||||||||||||
The following table provides a summary of the Company’s intangible assets with definite lives: | |||||||||||||||||
March 31, 2015 | December 31, 2014 | ||||||||||||||||
Cost | Accumulated | Cost | Accumulated | ||||||||||||||
Amortization | Amortization | ||||||||||||||||
Non-compete agreement | $ | 100 | $ | 96 | $ | 100 | $ | 93 | |||||||||
Fusion technology | 9,242 | 1,155 | 9,242 | 924 | |||||||||||||
Clamp & probe technology | 829 | 345 | 829 | 276 | |||||||||||||
Estech trade name | 208 | 208 | 208 | 208 | |||||||||||||
Total | $ | 10,379 | $ | 1,804 | $ | 10,379 | $ | 1,501 | |||||||||
Amortization expense related to intangible assets with definite lives was $303 and $355 for the three months ended March 31, 2015 and 2014, respectively. | |||||||||||||||||
Future amortization expense related to intangible assets with definite lives is projected as follows: | |||||||||||||||||
2015 | $ | 905 | April 1, 2015 through December 31, 2015 | ||||||||||||||
2016 | 1,201 | ||||||||||||||||
2017 | 924 | ||||||||||||||||
2018 | 924 | ||||||||||||||||
2019 | 924 | ||||||||||||||||
2020 and thereafter | 3,697 | ||||||||||||||||
Total | $ | 8,575 | |||||||||||||||
Accrued_Liabilities
Accrued Liabilities | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Payables and Accruals [Abstract] | |||||||||
Accrued Liabilities | 5. ACCRUED LIABILITIES | ||||||||
Accrued liabilities consisted of the following: | |||||||||
March 31, | December 31, | ||||||||
2015 | 2014 | ||||||||
Accrued commissions | $ | 2,975 | $ | 4,477 | |||||
Accrued payroll and employee-related expenses | 2,467 | 2,281 | |||||||
Accrued bonus | 1,636 | 4,915 | |||||||
Accrued taxes and value-added taxes payable | 814 | 1,272 | |||||||
Accrued royalties | 540 | 442 | |||||||
Other accrued liabilities | 276 | 399 | |||||||
Accrued non-employee stock options | 134 | 120 | |||||||
Sales returns allowance | 132 | 135 | |||||||
Total | $ | 8,974 | $ | 14,041 | |||||
Indebtedness
Indebtedness | 3 Months Ended | ||||||
Mar. 31, 2015 | |||||||
Debt Disclosure [Abstract] | |||||||
Indebtedness | 6. INDEBTEDNESS | ||||||
The Company has a debt agreement with Silicon Valley Bank (SVB). The agreement, as amended, restated and modified, includes a $15,000 revolving credit facility which matures on April 30, 2018. Borrowing availability under the revolving credit facility is based on the lesser of $15,000 or a borrowing base calculation as defined by the agreement. As of March 31, 2015 the Company had no borrowings under the revolving credit facility and had borrowing availability of approximately $14,074. | |||||||
Effective March 31, 2015, the Company and SVB entered into an Eighth Loan Modification Agreement (Loan Modification Agreement) which sets forth certain amendments to the Company’s credit facility. The Loan Modification Agreement provides for (i) an increase in the limit of outstanding letters of credit from $1,000 to $2,000, (ii) an extension of the revolving line maturity date from April 30, 2016 to April 30, 2018 and (iii) modifications to certain covenants and other terms of the agreement. | |||||||
As of March 31, 2015 and December 31, 2014 the Company had an outstanding letter of credit of €75 issued to its European subsidiary’s corporate credit card program provider which will expire on June 30, 2015. | |||||||
As of March 31, 2015 the Company had capital leases for computer and office equipment that expire at various terms through 2020. The cost of the assets under lease was $197. The assets are depreciated over their estimated useful lives, which equal the terms of the leases. Accumulated amortization on the capital leases was $71 at March 31, 2015. | |||||||
Future maturities on capital lease obligations are projected as follows: | |||||||
2015 | $ | 39 | April 1, 2015 through December 31, 2015 | ||||
2016 | 52 | ||||||
2017 | 32 | ||||||
2018 | 18 | ||||||
2019 | 8 | ||||||
2020 | 2 | ||||||
Total payments | $ | 151 | |||||
Imputed interest | (12 | ) | |||||
Net capital lease obligations | $ | 139 | |||||
Commitments_and_Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2015 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 7. COMMITMENTS AND CONTINGENCIES |
Lease Commitments | |
The Company leases various types of office, manufacturing and warehouse facilities and equipment under noncancelable operating leases that expire at various terms through 2021. | |
In August 2014 the Company and LM-VP AtriCure, LLC (Landlord), a third party unrelated to the Company, entered into a new building lease (Mason Lease) in order to re-locate its headquarters and West Chester, Ohio facilities from their current location to a building to be constructed on Innovation Way in Mason, Ohio and occupied exclusively by the Company. | |
The term of the Mason Lease is fifteen years with three separate five-year renewal options, at the Company’s option, and begins upon substantial completion of the construction of the building (Commencement Date). The amount of initial annual base rent of $1,353 is payable monthly beginning on the Commencement Date and is subject to a 2% increase each year during the Lease’s initial term. Upon each renewal, the amount of rent payable will be agreed upon by the Company and Landlord or, if not so agreed upon, by an appraiser. The size of the building subject to the Lease is expected to be approximately 92 square feet. | |
Under the Mason Lease, the Company is responsible for paying real estate taxes, insurance, utilities, operating expenses and most building repairs and maintenance. The Company is also responsible for paying the first $750 of construction-related tenant improvement costs, as well as amounts in excess of the estimated total cost of construction, as defined by the Mason Lease. On the Commencement Date, the Company is required to provide a letter of credit to the Landlord in the amount of $1,250, which amount may decrease or be removed entirely based on the Company’s financial performance. The Company is deemed the owner of the project during the construction period. As a result, approximately $5,936 and $3,941 of project costs incurred to date to construct the building are included in property and equipment and the financing obligation is included in other current liabilities in the Condensed Consolidated Balance Sheets as of March 31, 2015 and December 31, 2014, respectively. An increase in purchases of building under construction and proceeds from the construction financing obligation were also included in the Condensed Consolidated Statement of Cash Flows as of March 31, 2015. | |
Royalty Agreements | |
The Company has certain royalty agreements in place with terms that include payment of royalties based on product revenue from sales of specified current products. The royalty agreements have effective dates as early as 2003 and terms ranging from three years to at least twenty years. The royalties range from 0.75% to 5% of specified product sales. One of the agreements includes minimum quarterly payments of $50 through 2015 and a maximum of $2,000 in total royalties over the term of the agreement. Parties to the royalty agreements have the right at any time to terminate the agreement immediately for cause. Royalty expense of $427 and $307 was recorded as part of cost of revenue for the three months ended March 31, 2015 and 2014, respectively. | |
Purchase Agreements | |
The Company enters into standard purchase agreements with certain vendors in the ordinary course of business. Outstanding commitments at March 31, 2015 were not significant. | |
Legal | |
The Company may, from time to time, become a party to legal proceedings. |
Income_Tax_Provision
Income Tax Provision | 3 Months Ended |
Mar. 31, 2015 | |
Income Tax Disclosure [Abstract] | |
Income Tax Provision | 8. INCOME TAX PROVISION |
The Company files federal, state, and foreign income tax returns in jurisdictions with varying statutes of limitations. Income taxes are computed using the asset and liability method in accordance with FASB ASC 740, “Income Taxes”, under which deferred income taxes are provided for the temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities. Deferred taxes are measured using provisions of currently enacted tax laws. A valuation allowance against deferred tax assets is recorded when it is more-likely-than-not that such assets will not be fully realized. The Company has recorded a full valuation allowance against its net deferred tax assets as it is more-likely-than-not that the benefit of the deferred tax assets will not be recognized in future periods. Tax credits are accounted for as a reduction of income taxes in the year in which the credit originates. The Company does not expect any significant unrecognized tax benefits to arise over the next twelve months. | |
The Company’s provision for income taxes for continuing operations in interim periods is computed by applying its estimated annual effective rate against its loss before income tax (expense) benefit for the period. In addition, non-recurring or discrete items are recorded during the period in which they occur. The effective tax rate for the three months ended March 31, 2015 and 2014 was (0.11%) and (0.35%), respectively. | |
The Company has not had to accrue any interest and penalties related to unrecognized income tax benefits as a result of offsetting of net operating losses. However, if the situation occurs, the Company will recognize interest and penalties within the income tax expense (benefit) line in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss and within the related tax liability line in the Condensed Consolidated Balance Sheets. |
Equity_Compensation_Plans
Equity Compensation Plans | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||
Equity Compensation Plans | 9. EQUITY COMPENSATION PLANS | ||||||||
The Company has several share-based incentive plans: the 2001 Stock Option Plan (2001 Plan), the 2005 Equity Incentive Plan (2005 Plan), the Amended and Restated 2014 Stock Incentive Plan (2014 Plan) and the 2008 Employee Stock Purchase Plan (ESPP). | |||||||||
2001 Plan, 2005 Plan and 2014 Plan | |||||||||
Neither the 2001 Plan nor 2005 Plan is currently used for granting incentives. The Company granted awards under the 2005 Plan until the 2014 Annual Meeting of Stockholders at which stockholders adopted the 2014 Plan. Pursuant to its terms, the 2014 Plan supersedes and replaces the 2005 Plan. Under the 2014 Plan, the Board of Directors may grant incentive stock options to employees and any parent or subsidiary’s employees, and may grant nonstatutory stock options, restricted stock or stock appreciation rights to employees, directors and consultants of the Company and any parent or subsidiary’s employees, directors and consultants. The administrator (currently the Compensation Committee of the Board of Directors) has the power to determine the terms of any awards, including the exercise price of options, the number of shares subject to each award, the exercisability of the awards and the form of consideration. As of March 31, 2015 8,949 shares of common stock had been reserved for issuance under the 2014 Plan. | |||||||||
Options granted under the plans generally expire ten years from the date of grant. Options granted from the 2005 Plan and 2014 Plan generally vest at a rate of 25% on the first anniversary date of the grant and ratably each month thereafter over the following three years. Restricted stock awards granted under the 2005 Plan and 2014 Plan generally vest 25% annually over four years from date of grant. | |||||||||
Employee Stock Purchase Plan (ESPP) | |||||||||
During 2008 the Company established the Employee Stock Purchase Plan which is available to eligible employees as defined in the ESPP. Under the ESPP, shares of the Company’s common stock may be purchased at a discount (currently 15%) of the lesser of the closing price of the Company’s common stock on the first trading day or the last trading day of the offering period. The offering period (currently six months) and the offering price are subject to change. Participants may not purchase more than $25 of the Company’s common stock in a calendar year and, effective January 1, 2014, may not purchase more than 3 shares during an offering period. Beginning on January 1, 2009 and on the first day of each fiscal year thereafter during the term of the ESPP, the number of shares available for sale under the ESPP shall be increased by the lesser of (i) two percent (2%) of the Company’s outstanding shares of common stock as of the close of business on the last business day of the prior calendar year, not to exceed 600 shares, or (ii) a lesser amount determined by the Board of Directors. At March 31, 2015 there were 578 shares available for future issuance under the ESPP. | |||||||||
Valuation and Expense Information Under FASB ASC 718 | |||||||||
The following table summarizes share-based compensation expense related to employee share-based compensation under FASB ASC 718 for the three months ended March 31, 2015 and 2014. This expense was allocated as follows: | |||||||||
Three Months Ended March 31, | |||||||||
2015 | 2014 | ||||||||
Cost of revenue | $ | 90 | $ | 71 | |||||
Research and development expenses | 289 | 132 | |||||||
Selling, general and administrative expenses | 1,345 | 1,939 | |||||||
Total share-based compensation expense related to employees | $ | 1,724 | $ | 2,142 | |||||
Segment_and_Geographic_Informa
Segment and Geographic Information | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Segment Reporting [Abstract] | |||||||||
Segment and Geographic Information | 10. SEGMENT AND GEOGRAPHIC INFORMATION | ||||||||
The Company evaluates reporting segments in accordance with FASB ASC 280, “Segment Reporting”. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. These devices are developed and marketed to a broad base of medical centers in the United States and internationally. Management considers all such sales to be part of a single reportable segment. Revenue attributed to geographic areas is based on the location of the customers to whom products are sold. | |||||||||
Revenue by geographic area was as follows: | |||||||||
Three Months Ended March 31, | |||||||||
2015 | 2014 | ||||||||
United States | $ | 22,923 | $ | 18,143 | |||||
Europe | 4,416 | 4,308 | |||||||
Asia | 2,300 | 2,292 | |||||||
Other international | 247 | 104 | |||||||
Total international | 6,963 | 6,704 | |||||||
Total revenue | $ | 29,886 | $ | 24,847 | |||||
Domestic revenue by product type was as follows: | |||||||||
Three Months Ended March 31, | |||||||||
2015 | 2014 | ||||||||
Open-heart ablation | $ | 12,354 | $ | 10,377 | |||||
Minimally invasive ablation | 4,347 | 3,448 | |||||||
AtriClip | 5,503 | 3,620 | |||||||
Total ablation and AtriClip | 22,204 | 17,445 | |||||||
Valve tools | 719 | 698 | |||||||
Total domestic | $ | 22,923 | $ | 18,143 | |||||
International revenue by product type was as follows: | |||||||||
Three Months Ended March 31, | |||||||||
2015 | 2014 | ||||||||
Open-heart ablation | $ | 4,216 | $ | 3,971 | |||||
Minimally invasive ablation | 1,968 | 2,003 | |||||||
AtriClip | 671 | 443 | |||||||
Total ablation and AtriClip | 6,855 | 6,417 | |||||||
Valve tools | 108 | 287 | |||||||
Total international | $ | 6,963 | $ | 6,704 | |||||
The majority of the Company’s long-lived assets are located in the United States. |
Public_Offerings_of_Common_Sto
Public Offerings of Common Stock | 3 Months Ended |
Mar. 31, 2015 | |
Equity [Abstract] | |
Public Offerings of Common Stock | 11. PUBLIC OFFERINGS OF COMMON STOCK |
In February 2014 the Company completed a public offering of common stock under its January 2014 shelf registration. The Company sold 3,661 shares of common stock, par value $0.001 per share, at a price of $19.25 per share, generating proceeds of $65,830 after expenses. Offering costs were recorded in additional paid in capital to offset proceeds. |
Description_of_Business_and_Su1
Description of Business and Summary of Significant Accounting Policies (Policies) | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Accounting Policies [Abstract] | |||||||||
Nature of the Business | Nature of the Business—AtriCure, Inc. was incorporated in the State of Delaware on October 31, 2000. The “Company” or “AtriCure” consists of AtriCure, Inc. and its wholly-owned subsidiaries. The Company is an innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM). The Company sells its products to medical centers globally through a direct sales force and distributors. | ||||||||
Basis of Presentation | Basis of Presentation—The accompanying interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC). The accompanying interim financial statements are unaudited, but in the opinion of the Company’s management, contain all of the normal, recurring adjustments considered necessary to present fairly the financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America (GAAP) applicable to interim periods. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been omitted or condensed. The Company believes the disclosures herein are adequate to make the information presented not misleading. Results of operations are not necessarily indicative of the results expected for the full fiscal year or for any future period. | ||||||||
The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the audited financial statements of the Company included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC. | |||||||||
Principles of Consolidation | Principles of Consolidation—The Condensed Consolidated Financial Statements include the accounts of the Company, AtriCure, LLC, the Company’s wholly-owned subsidiary organized in the State of Delaware, Endoscopic Technologies, LLC, the Company’s wholly-owned subsidiary organized in the State of Delaware, and AtriCure Europe B.V. (AtriCure Europe), the Company’s wholly-owned subsidiary incorporated in the Netherlands. All intercompany accounts and transactions have been eliminated in consolidation. | ||||||||
Cash and Cash Equivalents | Cash and Cash Equivalents—The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents. | ||||||||
Investments | Investments—The Company places its investments primarily in U.S. Government agencies and securities, corporate bonds and commercial paper. The Company classifies all investments as available-for-sale. Investments with maturities of less than one year are classified as short-term investments. Investments are recorded at fair value, with unrealized gains and losses recorded as accumulated other comprehensive income (loss). The Company recognizes gains and losses when these securities are sold using the specific identification method and includes them in interest income or expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss. | ||||||||
Revenue Recognition | Revenue Recognition—The Company accounts for revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 605, “Revenue Recognition” (ASC 605). The Company recognizes revenue when all of the following criteria are met: (i) there is persuasive evidence that an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectability is reasonably assured. | ||||||||
Pursuant to the Company’s standard terms of sale, revenue is recognized when title to the goods and risk of loss transfers to customers and there are no remaining obligations that will affect the customers’ final acceptance of the sale. Generally, the Company’s standard terms of sale define the transfer of title and risk of loss to occur upon shipment to the respective customer. The Company generally does not maintain any post-shipping obligations to the recipients of the products. No installation, calibration or testing of this equipment is performed by the Company subsequent to shipment to the customer in order to render it operational. | |||||||||
Revenue includes shipping and handling revenue of $247 and $227 for the three months ended March 31, 2015 and 2014, respectively. Cost of freight for shipments made to customers is included in cost of revenue. Sales and other value-added taxes collected from customers and remitted to governmental authorities are excluded from revenue. The Company sells its products primarily through a direct sales force, with certain international markets sold through distributors. Terms of sale are generally consistent for both end-users and distributors except that payment terms are generally net 30 days for end-users and net 60 days for distributors. | |||||||||
Sales Returns and Allowances | Sales Returns and Allowances—The Company maintains a provision for sales returns and allowances to account for potential returns of defective or damaged products, products shipped in error and invoice adjustments. The Company estimates such provision quarterly based primarily on a specific identification basis, in addition to estimating a general reserve. Increases to the provision result in a reduction of revenue. The provision is included in accrued liabilities in the Condensed Consolidated Balance Sheets. | ||||||||
Allowance for Doubtful Accounts Receivable | Allowance for Doubtful Accounts Receivable—The Company evaluates the collectability of accounts receivable in order to determine the appropriate reserve for doubtful accounts. In determining the amount of the reserve, the Company considers aging of account balances, historical credit losses, customer-specific information and other relevant factors. An increase to the allowance for doubtful accounts results in a corresponding increase in expense. The Company reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables against the allowance when all attempts to collect the receivable have failed. The Company’s history of write-offs against the allowance has not been significant. | ||||||||
Inventories | Inventories—Inventories are stated at the lower of cost or market using approximate costs based on the first-in, first-out cost method (FIFO) and consist of raw materials, work in process and finished goods. The Company’s industry is characterized by rapid product development and frequent new product introductions. Uncertain timing of product approvals, variability in product launch strategies and variation in product utilization all impact excess and obsolete inventory. An inventory reserve based on product usage is estimated and recorded quarterly for excess, slow moving and obsolete inventory, as well as inventory with a carrying value in excess of its net realizable value. Write-offs are recorded when a product is destroyed. The Company’s history of write-offs against the reserve has not been significant. | ||||||||
Inventories consist of the following: | |||||||||
March 31, | December 31, | ||||||||
2015 | 2014 | ||||||||
Raw materials | $ | 4,484 | $ | 4,429 | |||||
Work in process | 1,169 | 1,397 | |||||||
Finished goods | 9,453 | 8,431 | |||||||
Inventories | $ | 15,106 | $ | 14,257 | |||||
Property and Equipment | Property and Equipment—Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method of depreciation for financial reporting purposes and applied over the estimated useful lives of the assets. The estimated useful life by major asset category is the following: generators and other capital equipment, machinery, equipment and vehicles is three to seven years, computer and other office equipment is three years, furniture and fixtures is three to seven years and leasehold improvements and equipment leased under a capital lease are the shorter of their useful life or remaining lease term. The Company reassesses the useful lives of property and equipment annually, and assets are retired if they are no longer being used. Maintenance and repair costs are expensed as incurred. | ||||||||
Generators and other capital equipment (such as the Company’s switchbox units and cryosurgical consoles) are loaned at no cost to direct customers that use the Company’s disposable products. Depreciation of such assets is included in cost of revenue. The estimated useful lives of this equipment are based on anticipated usage by customers and the timing and impact of expected new technology rollouts by the Company. To the extent the Company experiences changes in the usage of this equipment or introduces new technologies, the estimated useful lives of this equipment may change in a future period. Depreciation related to these generators was $620 and $461 for the three months ended March 31, 2015 and 2014, respectively. As of March 31, 2015 and December 31, 2014, the net carrying amount of loaned equipment included in net property and equipment in the Condensed Consolidated Balance Sheets was $4,123 and $4,141, respectively. | |||||||||
The Company reviews property and equipment for impairment using its best estimates based on reasonable and supportable assumptions and projections. | |||||||||
Intangible Assets | Intangible Assets—Intangible assets with determinable useful lives are amortized on a straight-line basis over the estimated periods benefited. The Company reviews intangible assets for impairment using its best estimates based on reasonable and supportable assumptions and projections. | ||||||||
Goodwill | Goodwill—Goodwill represents the excess of purchase price over the fair value of the net assets acquired in business combinations. The Company tests goodwill for impairment annually on November 30, or more often if impairment indicators are present. The Company’s goodwill is accounted for in a single reporting unit representing the Company as a whole. | ||||||||
Other Current Liabilities and Current Maturities of Capital Leases | Other Current Liabilities and Current Maturities of Capital Leases—Other current liabilities consist of a financing obligation related to the construction of the Company’s new headquarters (see Note 7—Commitments and Contingencies). Current maturities of capital leases consist of capital lease obligations with maturities of less than one year (see Note 6—Indebtedness). | ||||||||
Other Income | Other Income—Other income consists primarily of foreign currency transaction gains and losses, grant income and non-employee option gains and losses related to the fair market value change for fully vested options outstanding for consultants which are accounted for as free-standing derivatives. | ||||||||
The Company recorded net foreign currency transaction (losses) gains of ($163) and $5 for the three months ended March 31, 2015 and 2014, respectively, primarily in connection with settlements of its intercompany balance with AtriCure Europe. | |||||||||
The Company periodically is awarded grants to support research and development activities or education activities. The Company recognizes grant income when the funds are earned. The Company recorded grant income of $35 and $363 during the three months ended March 31, 2015 and 2014, respectively. | |||||||||
The Company historically issued stock options to non-employee consultants as a form of compensation for services provided to the Company. Because the non-employee options require settlement by the Company’s delivery of registered shares and because the tax withholding provisions in the awards allow the options to be partially net-cash settled, these options, when vested, are no longer eligible for equity classification and are, thus, subsequently accounted for as derivative liabilities under FASB ASC 815, “Derivatives and Hedging” (ASC 815) until the awards are ultimately either exercised or forfeited. Accordingly, the vested non-employee options are classified as liabilities and remeasured at fair value through earnings at each reporting period. During the three months ended March 31, 2015 and 2014, $13 and ($98), respectively, of expense (income) was recorded as a result of the remeasurement of the fair value of these fully vested stock options. | |||||||||
Taxes | Taxes—Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in the period that includes the enactment date. | ||||||||
The Company’s estimate of the valuation allowance for deferred tax assets requires it to make significant estimates and judgments about its future operating results. Deferred tax assets are reduced by valuation allowances if, based on the consideration of all available evidence, it is more-likely-than-not that some portion of the deferred tax asset will not be realized. Significant weight is given to evidence that can be objectively verified. The Company evaluates deferred tax assets on a quarterly basis to determine if valuation allowances are required by considering all available evidence. Deferred tax assets are realized by having sufficient future taxable income to allow the related tax benefits to reduce taxes otherwise payable. The sources of taxable income that may be available to realize the benefit of deferred tax assets are future reversals of existing taxable temporary differences, future taxable income, exclusive of reversing temporary differences and carryforwards, taxable income in carry-back years and tax planning strategies that are both prudent and feasible. In evaluating whether to record a valuation allowance, the applicable accounting standards deem that the existence of cumulative losses in recent years is a significant piece of objectively verifiable negative evidence that must be overcome by objectively verifiable positive evidence to avoid the need to record a valuation allowance. The Company has recorded a full valuation allowance against its net deferred tax assets as it is more-likely-than-not that the benefit of the deferred tax assets will not be recognized in future periods. | |||||||||
A provision of The Patient Protection and Affordable Care Act enacted in 2010, as amended (Affordable Care Act), requires manufacturers of medical devices to pay an excise tax on all U.S. medical device sales. The Company’s expense related to the medical device excise tax, which was recorded in cost of revenue, was $155 and $114 for the three months ended March 31, 2015 and 2014, respectively. | |||||||||
Net Loss Per Share | Net Loss Per Share—Basic and diluted net loss per share is computed in accordance with FASB ASC 260, “Earnings Per Share” (ASC 260) by dividing the net loss by the weighted average number of common shares outstanding during the period. Since the Company has experienced net losses for all periods presented, net loss per share excludes the effect of 4,320 and 3,762 options and restricted stock shares as of March 31, 2015 and 2014, respectively, because they are anti-dilutive. Therefore the number of shares calculated for basic net loss per share is also used for the diluted net loss per share calculation. | ||||||||
Comprehensive Loss and Accumulated Other Comprehensive Loss | Comprehensive Loss and Accumulated Other Comprehensive Loss—In addition to net losses, the comprehensive loss includes foreign currency translation adjustments and unrealized gains and losses on investments. | ||||||||
Accumulated other comprehensive income (loss) consisted of the following: | |||||||||
Three Months Ended March 31, | |||||||||
2015 | 2014 | ||||||||
Total accumulated other comprehensive loss at beginning of period | $ | (348 | ) | $ | (139 | ) | |||
Unrealized Loss on Investments | |||||||||
Balance at beginning of period | $ | (54 | ) | $ | (6 | ) | |||
Other comprehensive income (loss) before reclassifications | 37 | (2 | ) | ||||||
Amounts reclassified from accumulated other comprehensive income (loss) to other income | — | — | |||||||
Balance at end of period | $ | (17 | ) | $ | (8 | ) | |||
Foreign Currency Translation Adjustment | |||||||||
Balance at beginning of period | $ | (294 | ) | $ | (133 | ) | |||
Other comprehensive loss before reclassifications | (324 | ) | (3 | ) | |||||
Amounts reclassified from accumulated other comprehensive loss to other income (expense) | (163 | ) | 5 | ||||||
Balance at end of period | $ | (781 | ) | $ | (131 | ) | |||
Total accumulated other comprehensive loss at end of period | $ | (798 | ) | $ | (139 | ) | |||
Research and Development | Research and Development—Research and development costs are expensed as incurred. These costs include compensation and other internal and external costs associated with the development and research related to new and existing products or concepts, preclinical studies, clinical trials, healthcare compliance and regulatory affairs. | ||||||||
Advertising Costs | Advertising Costs—The Company expenses advertising costs as incurred. Advertising costs were not significant during the three months ended March 31, 2015 and 2014. | ||||||||
Share-Based Compensation | Share-Based Compensation—The Company follows FASB ASC 718, “Compensation-Stock Compensation” (ASC 718) to record share-based compensation for all employee share-based payment awards, including stock options, restricted stock, performance shares and stock purchases related to an employee stock purchase plan, based on estimated fair values. The Company’s share-based compensation expense recognized under ASC 718 for the three months ended March 31, 2015 and 2014 was $1,724 and $2,142, respectively, on a before and after tax basis. | ||||||||
FASB ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s Condensed Consolidated Statement of Operations and Comprehensive Loss. The expense has been reduced for estimated forfeitures. FASB ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. | |||||||||
The Company estimates the fair value of time-based options on the date of grant using the Black-Scholes option-pricing model (Black-Scholes model). The Company’s determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price, as well as assumptions regarding a number of subjective variables. These variables include, but are not limited to, the Company’s expected stock price volatility over the term of the awards and actual and projected employee stock option exercise behaviors. The fair value of market-based performance option grants is estimated at the date of grant using a Monte-Carlo simulation. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Condensed Consolidated Statements of Operations and Comprehensive Loss. | |||||||||
The Company estimates the fair value of restricted stock based upon the grant date closing market price of the Company’s common stock. The Company’s determination of fair value is affected by the Company’s stock price as well as assumptions regarding the number of shares expected to be granted. | |||||||||
The Company also has an employee stock purchase plan (ESPP or the Plan) which is available to all eligible employees as defined by the Plan. Under the ESPP, shares of the Company’s common stock may be purchased at a discount. The Company estimates the number of shares to be purchased under the Plan and records compensation expense based upon the fair value of the stock at the beginning of the purchase period using the Black-Scholes model. | |||||||||
Use of Estimates | |||||||||
Use of Estimates—The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. | |||||||||
Fair Value Disclosures | Fair Value Disclosures—The Company classifies and records cash and investments in U.S. government agencies and securities as Level 1 within the fair value hierarchy. Accounts receivable, short-term other assets, accounts payable and accrued liabilities are also classified as Level 1. The carrying amounts of these assets and liabilities approximate their fair value due to their relatively short-term nature. Cash equivalents and investments in commercial paper are classified as Level 2 within the fair value hierarchy (see Note 3—Fair Value for further information). Significant unobservable inputs with respect to the fair value measurement of the Level 3 non-employee stock options are developed using Company data. When an input is changed, the Black-Scholes model is updated and the results are analyzed for reasonableness. |
Description_of_Business_and_Su2
Description of Business and Summary of Significant Accounting Policies (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Accounting Policies [Abstract] | |||||||||
Summary of Inventories | Inventories consist of the following: | ||||||||
March 31, | December 31, | ||||||||
2015 | 2014 | ||||||||
Raw materials | $ | 4,484 | $ | 4,429 | |||||
Work in process | 1,169 | 1,397 | |||||||
Finished goods | 9,453 | 8,431 | |||||||
Inventories | $ | 15,106 | $ | 14,257 | |||||
Accumulated Other Comprehensive Income (Loss) | Accumulated other comprehensive income (loss) consisted of the following: | ||||||||
Three Months Ended March 31, | |||||||||
2015 | 2014 | ||||||||
Total accumulated other comprehensive loss at beginning of period | $ | (348 | ) | $ | (139 | ) | |||
Unrealized Loss on Investments | |||||||||
Balance at beginning of period | $ | (54 | ) | $ | (6 | ) | |||
Other comprehensive income (loss) before reclassifications | 37 | (2 | ) | ||||||
Amounts reclassified from accumulated other comprehensive income (loss) to other income | — | — | |||||||
Balance at end of period | $ | (17 | ) | $ | (8 | ) | |||
Foreign Currency Translation Adjustment | |||||||||
Balance at beginning of period | $ | (294 | ) | $ | (133 | ) | |||
Other comprehensive loss before reclassifications | (324 | ) | (3 | ) | |||||
Amounts reclassified from accumulated other comprehensive loss to other income (expense) | (163 | ) | 5 | ||||||
Balance at end of period | $ | (781 | ) | $ | (131 | ) | |||
Total accumulated other comprehensive loss at end of period | $ | (798 | ) | $ | (139 | ) | |||
Fair_Value_Tables
Fair Value (Tables) | 3 Months Ended | ||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis | In accordance with ASC 820, the following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2015: | ||||||||||||||||
Quoted Prices in | Significant Other | Significant Other | Total | ||||||||||||||
Active Markets for | Observable Inputs | Unobservable | |||||||||||||||
Identical Assets | (Level 2) | Inputs (Level 3) | |||||||||||||||
(Level 1) | |||||||||||||||||
Assets: | |||||||||||||||||
Money market funds | $ | — | $ | 20,370 | $ | — | $ | 20,370 | |||||||||
U.S. government agencies and securities | 1,021 | — | — | 1,021 | |||||||||||||
Corporate bonds | — | 33,178 | — | 33,178 | |||||||||||||
Total assets | $ | 1,021 | $ | 53,548 | $ | — | $ | 54,569 | |||||||||
Liabilities: | |||||||||||||||||
Derivative instruments | $ | — | $ | — | $ | 134 | $ | 134 | |||||||||
Total liabilities | $ | — | $ | — | $ | 134 | $ | 134 | |||||||||
There were no changes in the levels or methodology of measurement of financial assets and liabilities during the three-month period ended March 31, 2015. | |||||||||||||||||
In accordance with ASC 820, the following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2014: | |||||||||||||||||
Quoted Prices in | Significant Other | Significant Other | Total | ||||||||||||||
Active Markets for | Observable Inputs | Unobservable | |||||||||||||||
Identical Assets | (Level 2) | Inputs (Level 3) | |||||||||||||||
(Level 1) | |||||||||||||||||
Assets: | |||||||||||||||||
Money market funds | $ | — | $ | 23,692 | $ | — | $ | 23,692 | |||||||||
Commercial paper | — | 1,800 | — | 1,800 | |||||||||||||
U.S. government agencies and securities | 3,022 | — | — | 3,022 | |||||||||||||
Corporate bonds | — | 35,337 | — | 35,337 | |||||||||||||
Total assets | $ | 3,022 | $ | 60,829 | $ | — | $ | 63,851 | |||||||||
Liabilities: | |||||||||||||||||
Derivative instruments | $ | — | $ | — | $ | 120 | $ | 120 | |||||||||
Acquisition-related contingent consideration | — | — | — | — | |||||||||||||
Total liabilities | $ | — | $ | — | $ | 120 | $ | 120 | |||||||||
Assumptions Used for Estimating Fair Value of Level 3 Liabilities | The fair value of the Level 3 liabilities is estimated using the Black-Scholes model including the following assumptions: | ||||||||||||||||
As of March 31, 2015 | As of December 31, 2014 | ||||||||||||||||
Risk free interest rate | 0.13 | % | 0.07 | % | |||||||||||||
Expected life of option (years) | 0.46 | 0.7 | |||||||||||||||
Expected volatility of stock | 38 | % | 39.91 | % | |||||||||||||
Dividend yield | 0 | % | 0 | % | |||||||||||||
Level 3 Fair Value Measurements Using Significant Other Unobservable Inputs for Derivative Instruments | In accordance with ASC 820, the following table represents the Company’s Level 3 fair value measurements using significant other unobservable inputs for derivative instruments as of March 31, 2015: | ||||||||||||||||
Beginning Balance—January 1, 2015 | $ | 120 | |||||||||||||||
Total losses included in earnings | 14 | ||||||||||||||||
Exercises | — | ||||||||||||||||
Reclassification from equity to liability when fully vested | — | ||||||||||||||||
Ending Balance—March 31, 2015 | $ | 134 | |||||||||||||||
In accordance with ASC 820, the following table represents the Company’s Level 3 fair value measurements using significant other unobservable inputs for derivative instruments as of December 31, 2014: | |||||||||||||||||
Beginning Balance—January 1, 2014 | $ | 350 | |||||||||||||||
Total gains included in earnings | (183 | ) | |||||||||||||||
Exercises | (47 | ) | |||||||||||||||
Reclassification from equity to liability when fully vested | — | ||||||||||||||||
Ending Balance—December 31, 2014 | $ | 120 | |||||||||||||||
Level 3 Fair Value Measurements Using Significant Other Unobservable Inputs for Acquisition Related Contingent Consideration | The following table represents the Company’s Level 3 fair value measurements using significant other unobservable inputs for acquisition-related contingent consideration as of December 31, 2014: | ||||||||||||||||
Beginning Balance—January 1, 2014 | $ | 8,032 | |||||||||||||||
Amounts acquired | — | ||||||||||||||||
Transfers in (out) of Level 3 | — | ||||||||||||||||
Changes in fair value included in earnings | (8,032 | ) | |||||||||||||||
Ending Balance—December 31, 2014 | $ | — | |||||||||||||||
Intangible_Assets_Tables
Intangible Assets (Tables) | 3 Months Ended | ||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||
Summary of Company's Intangible Assets with Definite Lives | The following table provides a summary of the Company’s intangible assets with definite lives: | ||||||||||||||||
March 31, 2015 | December 31, 2014 | ||||||||||||||||
Cost | Accumulated | Cost | Accumulated | ||||||||||||||
Amortization | Amortization | ||||||||||||||||
Non-compete agreement | $ | 100 | $ | 96 | $ | 100 | $ | 93 | |||||||||
Fusion technology | 9,242 | 1,155 | 9,242 | 924 | |||||||||||||
Clamp & probe technology | 829 | 345 | 829 | 276 | |||||||||||||
Estech trade name | 208 | 208 | 208 | 208 | |||||||||||||
Total | $ | 10,379 | $ | 1,804 | $ | 10,379 | $ | 1,501 | |||||||||
Future Amortization Expense Related to Intangible Assets with Definite Lives | Future amortization expense related to intangible assets with definite lives is projected as follows: | ||||||||||||||||
2015 | $ | 905 | April 1, 2015 through December 31, 2015 | ||||||||||||||
2016 | 1,201 | ||||||||||||||||
2017 | 924 | ||||||||||||||||
2018 | 924 | ||||||||||||||||
2019 | 924 | ||||||||||||||||
2020 and thereafter | 3,697 | ||||||||||||||||
Total | $ | 8,575 | |||||||||||||||
Accrued_Liabilities_Tables
Accrued Liabilities (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Payables and Accruals [Abstract] | |||||||||
Accrued Liabilities | Accrued liabilities consisted of the following: | ||||||||
March 31, | December 31, | ||||||||
2015 | 2014 | ||||||||
Accrued commissions | $ | 2,975 | $ | 4,477 | |||||
Accrued payroll and employee-related expenses | 2,467 | 2,281 | |||||||
Accrued bonus | 1,636 | 4,915 | |||||||
Accrued taxes and value-added taxes payable | 814 | 1,272 | |||||||
Accrued royalties | 540 | 442 | |||||||
Other accrued liabilities | 276 | 399 | |||||||
Accrued non-employee stock options | 134 | 120 | |||||||
Sales returns allowance | 132 | 135 | |||||||
Total | $ | 8,974 | $ | 14,041 | |||||
Indebtedness_Tables
Indebtedness (Tables) | 3 Months Ended | ||||||
Mar. 31, 2015 | |||||||
Debt Disclosure [Abstract] | |||||||
Future Maturities on Debt, Including Capital Lease Obligations | Future maturities on capital lease obligations are projected as follows: | ||||||
2015 | $ | 39 | April 1, 2015 through December 31, 2015 | ||||
2016 | 52 | ||||||
2017 | 32 | ||||||
2018 | 18 | ||||||
2019 | 8 | ||||||
2020 | 2 | ||||||
Total payments | $ | 151 | |||||
Imputed interest | (12 | ) | |||||
Net capital lease obligations | $ | 139 | |||||
Equity_Compensation_Plans_Tabl
Equity Compensation Plans (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||
Summary of Share-Based Compensation Expense Related to Employee Share-Based Compensation | The following table summarizes share-based compensation expense related to employee share-based compensation under FASB ASC 718 for the three months ended March 31, 2015 and 2014. This expense was allocated as follows: | ||||||||
Three Months Ended March 31, | |||||||||
2015 | 2014 | ||||||||
Cost of revenue | $ | 90 | $ | 71 | |||||
Research and development expenses | 289 | 132 | |||||||
Selling, general and administrative expenses | 1,345 | 1,939 | |||||||
Total share-based compensation expense related to employees | $ | 1,724 | $ | 2,142 | |||||
Segment_and_Geographic_Informa1
Segment and Geographic Information (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Segment Reporting [Abstract] | |||||||||
Summary of Revenue by Geographic Area | Revenue by geographic area was as follows: | ||||||||
Three Months Ended March 31, | |||||||||
2015 | 2014 | ||||||||
United States | $ | 22,923 | $ | 18,143 | |||||
Europe | 4,416 | 4,308 | |||||||
Asia | 2,300 | 2,292 | |||||||
Other international | 247 | 104 | |||||||
Total international | 6,963 | 6,704 | |||||||
Total revenue | $ | 29,886 | $ | 24,847 | |||||
Revenue by Product | Domestic revenue by product type was as follows: | ||||||||
Three Months Ended March 31, | |||||||||
2015 | 2014 | ||||||||
Open-heart ablation | $ | 12,354 | $ | 10,377 | |||||
Minimally invasive ablation | 4,347 | 3,448 | |||||||
AtriClip | 5,503 | 3,620 | |||||||
Total ablation and AtriClip | 22,204 | 17,445 | |||||||
Valve tools | 719 | 698 | |||||||
Total domestic | $ | 22,923 | $ | 18,143 | |||||
International revenue by product type was as follows: | |||||||||
Three Months Ended March 31, | |||||||||
2015 | 2014 | ||||||||
Open-heart ablation | $ | 4,216 | $ | 3,971 | |||||
Minimally invasive ablation | 1,968 | 2,003 | |||||||
AtriClip | 671 | 443 | |||||||
Total ablation and AtriClip | 6,855 | 6,417 | |||||||
Valve tools | 108 | 287 | |||||||
Total international | $ | 6,963 | $ | 6,704 | |||||
Description_of_Business_and_Su3
Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $) | 3 Months Ended | ||
In Thousands, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | Dec. 31, 2014 |
Description Of Business And Significant Accounting Policies [Line Items] | |||
Maturity period of short term investment | 1 year | ||
Shipping and handling revenue | $247 | $227 | |
Payment terms for end-users | 30 days | ||
Payment terms for distributors | 60 days | ||
Depreciation | 1,008 | 730 | |
Net carrying amount of loaned equipment | 13,874 | 11,552 | |
Net foreign currency transaction (losses) gains | -487 | 2 | |
Grant income | 35 | 363 | |
(Income) expense related to remeasurement of fair value of fully vested stock options | 13 | -98 | |
Company's expense related to the medical device excise tax | 155 | 114 | |
Options, restricted stock and performance based shares excluded from calculation of net loss per share | 4,320 | 3,762 | |
Share-based compensation expense recognized | 1,724 | 2,142 | |
Subsidiaries [Member] | |||
Description Of Business And Significant Accounting Policies [Line Items] | |||
Net foreign currency transaction (losses) gains | -163 | 5 | |
Computer and Other Office Equipment [Member] | |||
Description Of Business And Significant Accounting Policies [Line Items] | |||
Estimated useful life by major asset category | 3 years | ||
Generators [Member] | |||
Description Of Business And Significant Accounting Policies [Line Items] | |||
Depreciation | 620 | 461 | |
Carrying Amount of Loaned Equipment [Member] | |||
Description Of Business And Significant Accounting Policies [Line Items] | |||
Net carrying amount of loaned equipment | $4,123 | $4,141 | |
Minimum [Member] | Generators and Other Capital Equipment, Machinery, Equipment and Vehicles [Member] | |||
Description Of Business And Significant Accounting Policies [Line Items] | |||
Estimated useful life by major asset category | 3 years | ||
Minimum [Member] | Furniture and Fixtures [Member] | |||
Description Of Business And Significant Accounting Policies [Line Items] | |||
Estimated useful life by major asset category | 3 years | ||
Maximum [Member] | Generators and Other Capital Equipment, Machinery, Equipment and Vehicles [Member] | |||
Description Of Business And Significant Accounting Policies [Line Items] | |||
Estimated useful life by major asset category | 7 years | ||
Maximum [Member] | Furniture and Fixtures [Member] | |||
Description Of Business And Significant Accounting Policies [Line Items] | |||
Estimated useful life by major asset category | 7 years |
Description_of_Business_and_Su4
Description of Business and Summary of Significant Accounting Policies - Summary of Inventories (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Thousands, unless otherwise specified | ||
Inventory Disclosure [Abstract] | ||
Raw materials | $4,484 | $4,429 |
Work in process | 1,169 | 1,397 |
Finished goods | 9,453 | 8,431 |
Inventories | $15,106 | $14,257 |
Description_of_Business_and_Su5
Description of Business and Summary of Significant Accounting Policies - Accumulated Other Comprehensive Income (Loss) (Detail) (USD $) | 3 Months Ended | |||
In Thousands, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | Dec. 31, 2014 | Dec. 31, 2013 |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Beginning Balance | ($348) | ($139) | ||
Ending Balance | -798 | -139 | -348 | -139 |
Unrealized Loss on Investments [Member] | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Beginning Balance | -54 | -6 | ||
Other comprehensive income (loss) before reclassifications | 37 | -2 | ||
Ending Balance | -17 | -8 | ||
Foreign Currency Translation Adjustment [Member] | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Beginning Balance | -294 | -133 | ||
Other comprehensive income (loss) before reclassifications | -324 | -3 | ||
Amounts reclassified from accumulated other comprehensive loss to other income (expense) | -163 | 5 | ||
Ending Balance | ($781) | ($131) |
Fair_Value_Financial_Assets_an
Fair Value - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Thousands, unless otherwise specified | ||
Significant Other Unobservable Inputs (Level 3) [Member] | ||
Liabilities: | ||
Acquisition-related contingent consideration | $0 | $0 |
Fair Value, Measurements, Recurring [Member] | ||
Assets: | ||
Total assets | 54,569 | 63,851 |
Liabilities: | ||
Derivative instruments | 134 | 120 |
Acquisition-related contingent consideration | 0 | |
Total liabilities | 134 | 120 |
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member] | ||
Assets: | ||
Total assets | 20,370 | 23,692 |
Fair Value, Measurements, Recurring [Member] | Commercial Paper [Member] | ||
Assets: | ||
Total assets | 1,800 | |
Fair Value, Measurements, Recurring [Member] | U.S. Government Agencies and Securities [Member] | ||
Assets: | ||
Total assets | 1,021 | 3,022 |
Fair Value, Measurements, Recurring [Member] | Corporate Bonds [Member] | ||
Assets: | ||
Total assets | 33,178 | 35,337 |
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | ||
Assets: | ||
Total assets | 1,021 | 3,022 |
Liabilities: | ||
Acquisition-related contingent consideration | 0 | |
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | U.S. Government Agencies and Securities [Member] | ||
Assets: | ||
Total assets | 1,021 | 3,022 |
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | ||
Assets: | ||
Total assets | 53,548 | 60,829 |
Liabilities: | ||
Acquisition-related contingent consideration | 0 | |
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | Money Market Funds [Member] | ||
Assets: | ||
Total assets | 20,370 | 23,692 |
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | Commercial Paper [Member] | ||
Assets: | ||
Total assets | 1,800 | |
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | Corporate Bonds [Member] | ||
Assets: | ||
Total assets | 33,178 | 35,337 |
Fair Value, Measurements, Recurring [Member] | Significant Other Unobservable Inputs (Level 3) [Member] | ||
Liabilities: | ||
Derivative instruments | 134 | 120 |
Acquisition-related contingent consideration | 0 | |
Total liabilities | $134 | $120 |
Fair_Value_Assumptions_Used_fo
Fair Value - Assumptions Used for Estimating Fair Value of Level 3 Liabilities (Detail) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2015 | Dec. 31, 2014 | |
Fair Value Disclosures [Abstract] | ||
Risk free interest rate | 0.13% | 0.07% |
Expected life of option (years) | 5 months 16 days | 8 months 12 days |
Expected volatility of stock | 38.00% | 39.91% |
Dividend yield | 0.00% | 0.00% |
Fair_Value_Level_3_Fair_Value_
Fair Value - Level 3 Fair Value Measurements Using Significant Other Unobservable Inputs for Derivative Instruments (Detail) (USD $) | 3 Months Ended | 12 Months Ended |
In Thousands, unless otherwise specified | Mar. 31, 2015 | Dec. 31, 2014 |
Fair Value Disclosures [Abstract] | ||
Beginning Balance | $120 | $350 |
Total (gains) losses included in earnings | 14 | -183 |
Exercises | -47 | |
Reclassification from equity to liability when fully vested | 0 | 0 |
Ending Balance | $134 | $120 |
Fair_Value_Additional_Informat
Fair Value - Additional Information (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | |||
Significant Other Unobservable Inputs (Level 3) [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Acquisition-related contingent consideration | $0 | $0 | |
Maximum [Member] | Estech [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Acquisition-related contingent consideration | $26,000 |
Fair_Value_Level_3_Fair_Value_1
Fair Value - Level 3 Fair Value Measurements Using Significant Other Unobservable Inputs for Acquisition Related Contingent Consideration (Detail) (USD $) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 31, 2014 |
Debt Instrument Fair Value Carrying Value [Abstract] | |
Beginning Balance | $8,032 |
Amounts acquired | 0 |
Transfers in (out) of Level 3 | 0 |
Changes in fair value included in earnings | -8,032 |
Ending Balance | $0 |
Intangible_Assets_Summary_of_C
Intangible Assets - Summary of Company's Intangible Assets with Definite Lives (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Thousands, unless otherwise specified | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | $10,379 | $10,379 |
Accumulated Amortization | 1,804 | 1,501 |
Non-Compete Agreement [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | 100 | 100 |
Accumulated Amortization | 96 | 93 |
Fusion Technology [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | 9,242 | 9,242 |
Accumulated Amortization | 1,155 | 924 |
Clamp and Probe Technology [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | 829 | 829 |
Accumulated Amortization | 345 | 276 |
Estech Trade Name [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | 208 | 208 |
Accumulated Amortization | $208 | $208 |
Intangible_Assets_Additional_I
Intangible Assets - Additional Information (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Amortization of intangible assets | $303 | $355 |
Intangible_Assets_Future_Amort
Intangible Assets - Future Amortization Expense Related to Intangible Assets with Definite Lives (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Thousands, unless otherwise specified | ||
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Expected amortization expense April 1, 2015 through December 31, 2015 | $905 | |
Expected amortization expense in 2016 | 1,201 | |
Expected amortization expense in 2017 | 924 | |
Expected amortization expense in 2018 | 924 | |
Expected amortization expense in 2019 | 924 | |
Expected amortization expense in 2020 and thereafter | 3,697 | |
Total | $8,575 | $8,878 |
Accrued_Liabilities_Accrued_Li
Accrued Liabilities - Accrued Liabilities (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Thousands, unless otherwise specified | ||
Payables and Accruals [Abstract] | ||
Accrued commissions | $2,975 | $4,477 |
Accrued payroll and employee-related expenses | 2,467 | 2,281 |
Accrued bonus | 1,636 | 4,915 |
Accrued taxes and value-added taxes payable | 814 | 1,272 |
Accrued royalties | 540 | 442 |
Other accrued liabilities | 276 | 399 |
Accrued non-employee stock options | 134 | 120 |
Sales returns allowance | 132 | 135 |
Total | $8,974 | $14,041 |
Indebtedness_Additional_Inform
Indebtedness - Additional Information (Detail) | 3 Months Ended | 3 Months Ended | 0 Months Ended | |||||
Mar. 31, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Mar. 31, 2015 | Mar. 31, 2015 | Mar. 30, 2015 | Mar. 31, 2015 | Mar. 30, 2015 | |
USD ($) | EUR (€) | EUR (€) | Revolving Credit Facility [Member] | Eighth Loan Modification Agreement [Member] | Eighth Loan Modification Agreement [Member] | Eighth Loan Modification Agreement [Member] | Eighth Loan Modification Agreement [Member] | |
USD ($) | USD ($) | USD ($) | ||||||
Credit Facilities [Line Items] | ||||||||
Credit facility | $15,000,000 | |||||||
Letter of credit maturity date | 30-Apr-18 | 30-Apr-18 | 30-Apr-16 | |||||
Outstanding letters of credit limit | 2,000,000 | 1,000,000 | ||||||
Borrowings under the revolving credit facility, availability | 14,074,000 | |||||||
Borrowings under the revolving credit facility, outstanding | 0 | |||||||
Letter of credit outstanding | 75,000 | 75,000 | ||||||
Expiry of outstanding letter of credit | 30-Jun-15 | 30-Jun-15 | ||||||
Capital lease expiration period | 2020 | 2020 | ||||||
Cost of assets under lease | 197,000 | |||||||
Accumulated amortization on the capital leases | $71,000 |
Indebtedness_Future_Maturities
Indebtedness - Future Maturities on Debt, Including Capital Lease Obligations (Detail) (USD $) | Mar. 31, 2015 |
In Thousands, unless otherwise specified | |
Debt Disclosure [Abstract] | |
Capital lease obligations due April 1, 2015 through December 31, 2015 | $39 |
Capital lease obligations due 2016 | 52 |
Capital lease obligations due 2017 | 32 |
Capital lease obligations due 2018 | 18 |
Capital lease obligations due 2019 | 8 |
Capital lease obligations due thereafter | 2 |
Capital lease obligations total payments | 151 |
Imputed interest | -12 |
Net capital lease obligations | $139 |
Commitments_and_Contingencies_
Commitments and Contingencies - Additional Information (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | Dec. 31, 2014 |
Commitments and Contingencies [Line Items] | |||
Operating leases expire at various terms | 2021 | ||
Letter of credit to be issued to landlord, amount | $1,250 | ||
Royalty expense | 427 | 307 | |
Minimum [Member] | |||
Commitments and Contingencies [Line Items] | |||
Royalty rates | 0.75% | ||
Royalty payments | 50 | ||
Royalty agreement term | 3 years | ||
Maximum [Member] | |||
Commitments and Contingencies [Line Items] | |||
Royalty rates | 5.00% | ||
Royalty payments | 2,000 | ||
Royalty agreement term | 20 years | ||
Mason Lease [Member] | |||
Commitments and Contingencies [Line Items] | |||
Lease term period | 15 years | ||
Number of renewal options | 3 | ||
Lease renewal option period | 5 years | ||
Initial annual base rent | 1,353 | ||
Lease rate increase, percentage | 2.00% | ||
Area of lease | 92 | ||
Project cost included in the construction of building | 5,936 | 3,941 | |
Mason Lease [Member] | Leasehold Improvements [Member] | |||
Commitments and Contingencies [Line Items] | |||
Leases payable, amount | $750 |
Income_Tax_Provision_Additiona
Income Tax Provision - Additional Information (Detail) | 3 Months Ended | |
Mar. 31, 2015 | Mar. 31, 2014 | |
Income Tax Disclosure [Abstract] | ||
Effective tax rate | 0.11% | 0.35% |
Equity_Compensation_Plans_2001
Equity Compensation Plans - 2001 Plan, 2005 Plan and 2014 Plan - Additional Information (Detail) | 3 Months Ended |
In Thousands, unless otherwise specified | Mar. 31, 2015 |
2001 Plan [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Expiry of options from the date of grant | 10 years |
2005 Plan [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Expiry of options from the date of grant | 10 years |
Restricted stock awards granted annual vest rate | 25.00% |
2014 Plan [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Expiry of options from the date of grant | 10 years |
Restricted stock awards granted annual vest rate | 25.00% |
Common stock reserved for issuance | 8,949 |
Employee Stock Option [Member] | 2005 Plan [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Exercisable period beginning | 3 years |
Options granted exercisable cumulative | 25.00% |
Employee Stock Option [Member] | 2014 Plan [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Exercisable period beginning | 3 years |
Options granted exercisable cumulative | 25.00% |
Restricted Stock [Member] | 2005 Plan [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Options granted from the 2005 Plan generally vest | 4 years |
Restricted Stock [Member] | 2014 Plan [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Options granted from the 2005 Plan generally vest | 4 years |
Equity_Compensation_Plans_Empl
Equity Compensation Plans - Employee Stock Purchase Plan - Additional Information (Detail) (USD $) | 3 Months Ended |
In Thousands, except Share data, unless otherwise specified | Mar. 31, 2015 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Description of participants purchase limit | Participants may not purchase more than $25 of the Company's common stock in a calendar year and, effective January 1, 2014, may not purchase more than 3 shares during an offering period |
Participants purchase limit shares | 3,000 |
Offering period | 6 months |
ESPP [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Company's common stock may be purchased at a discount | 15.00% |
Participants purchase limit value | 25 |
Shares available for sale under the ESPP increased | 2.00% |
Outstanding shares of common stock exceed | 600,000 |
Shares available for future issuance under the ESPP | 578,000 |
Equity_Compensation_Plans_Summ
Equity Compensation Plans - Summary of Share-Based Compensation Expense Related to Employee Share-Based Compensation (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Total share-based compensation expense related to employees | $1,724 | $2,142 |
Cost of Revenue [Member] | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Total share-based compensation expense related to employees | 90 | 71 |
Research and Development Expenses [Member] | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Total share-based compensation expense related to employees | 289 | 132 |
Selling, General and Administrative Expenses [Member] | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Total share-based compensation expense related to employees | $1,345 | $1,939 |
Segment_and_Geographic_Informa2
Segment and Geographic Information - Summary of Revenue by Geographic Area (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Information About Revenue And Geographic Areas [Line Items] | ||
Revenue | $29,886 | $24,847 |
United States [Member] | ||
Information About Revenue And Geographic Areas [Line Items] | ||
Revenue | 22,923 | 18,143 |
Europe [Member] | ||
Information About Revenue And Geographic Areas [Line Items] | ||
Revenue | 4,416 | 4,308 |
Asia [Member] | ||
Information About Revenue And Geographic Areas [Line Items] | ||
Revenue | 2,300 | 2,292 |
Other International [Member] | ||
Information About Revenue And Geographic Areas [Line Items] | ||
Revenue | 247 | 104 |
International [Member] | ||
Information About Revenue And Geographic Areas [Line Items] | ||
Revenue | $6,963 | $6,704 |
Segment_and_Geographic_Informa3
Segment and Geographic Information - Revenue by Product (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Product Type Reporting Information [Line Items] | ||
Revenue | $29,886 | $24,847 |
United States [Member] | ||
Product Type Reporting Information [Line Items] | ||
Revenue | 22,923 | 18,143 |
United States [Member] | Open-heart Ablation [Member] | ||
Product Type Reporting Information [Line Items] | ||
Revenue | 12,354 | 10,377 |
United States [Member] | Minimally Invasive Ablation [Member] | ||
Product Type Reporting Information [Line Items] | ||
Revenue | 4,347 | 3,448 |
United States [Member] | AtriClip [Member] | ||
Product Type Reporting Information [Line Items] | ||
Revenue | 5,503 | 3,620 |
United States [Member] | Ablation and AtriClip [Member] | ||
Product Type Reporting Information [Line Items] | ||
Revenue | 22,204 | 17,445 |
United States [Member] | Valve Tools [Member] | ||
Product Type Reporting Information [Line Items] | ||
Revenue | 719 | 698 |
International [Member] | ||
Product Type Reporting Information [Line Items] | ||
Revenue | 6,963 | 6,704 |
International [Member] | Open-heart Ablation [Member] | ||
Product Type Reporting Information [Line Items] | ||
Revenue | 4,216 | 3,971 |
International [Member] | Minimally Invasive Ablation [Member] | ||
Product Type Reporting Information [Line Items] | ||
Revenue | 1,968 | 2,003 |
International [Member] | AtriClip [Member] | ||
Product Type Reporting Information [Line Items] | ||
Revenue | 671 | 443 |
International [Member] | Ablation and AtriClip [Member] | ||
Product Type Reporting Information [Line Items] | ||
Revenue | 6,855 | 6,417 |
International [Member] | Valve Tools [Member] | ||
Product Type Reporting Information [Line Items] | ||
Revenue | $108 | $287 |
Public_Offerings_of_Common_Sto1
Public Offerings of Common Stock - Additional Information (Detail) (USD $) | 1 Months Ended | 3 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Feb. 28, 2014 | Mar. 31, 2014 | Mar. 31, 2015 | Dec. 31, 2014 |
Equity [Abstract] | ||||
Common stock sold | 3,661 | |||
Common stock, par value | $0.00 | $0.00 | $0.00 | |
Common stock, price per share | $19.25 | |||
Proceeds from issuance of common stock | $65,830 | $65,872 |